{"ticker": {"uuid": "ea6f90ee-f127-429e-b2af-8d9e4052576e", "symbol": "MNKD", "name": "MannKind Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQX1djSXdqZGIyRm9BenF1N2xPN3NkNjZkSl9WZ1VRTzZuZ21GMy1vN1hCUXdXVWVqODZrQWEzUFc1Z3JlYUJnVGNzblRsN2lvNy04VGlLamYtTDJoeTI5djZKNWprNkN0Y0F3WkdRcDJDbkZEZjJIOGZSM2NLMzZGaS1fNE5IWGpRMEtDakZkYWh0T2pQeWNlclJ3QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T17:29:21+00:00", "published_display": "09 Jul 2026 17:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp looks beyond inhaled insulin as pipeline ambitions grow", "summary": "MannKind Corp is expanding its pipeline beyond its inhaled insulin product, Afrezza, by seeking new therapeutic applications for its Technosphere drug-delivery platform. While Afrezza remains the commercial foundation, the company is exploring other indications like pulmonary art", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mannkind-corp-looks-beyond-inhaled-insulin-as-pipeline-ambitions-grow/69715094", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:41:48", "published_display": "07 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Receives a Grant from Breakthrough T1D", "summary": "MannKind Corporation (MNKD) received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial, which evaluates inhaled insulin in newly diagnosed pediatric patients with type 1 diabetes. This grant provides external validation for Afrezza, MannKind's inhaled insulin", "url": "https://www.insidermonkey.com/blog/mannkind-mnkd-receives-a-grant-from-breakthrough-t1d-1794185/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:09:35", "published_display": "03 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Wins Breakthrough T1D Grant, Is The Stock Still 11% Undervalued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Stock Plummets After Partner United Therapeutics Unveils New \u2018Category Killer Product\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQX2cyYnVaVExIWG1QRjNUMVdkQ1Y2eW5VRzJ2WE13ckJXenVLV3F6ZFR4SEcyR2lsc2pveERra0ZxV3ZUUDZTNndrcXZ3aXFGenRmUkZacnM2THRPaTZ2dXdQR3k5ZDh6Q3dpUEV5cll0cUw3c1o2bTZmX2hvXzJkZEhaeDAxYV9id2hodTlQUUt2VWVtNzdMbzhKSFJTd3JXSVNwVGVRZWYxR0Q3aTJwT2ZrYThYU1ZvV2dIRlgzaXhGSzk5dndObW0wclU5QW9zQW5CeDhqQ0JuSm16Wlk5QlZ6aVdVdW0zNVh5MTJn?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-03T03:21:09+00:00", "published_display": "03 Jul 2026 03:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MannKind Corporation (MNKD) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQeE4zZ0lYdFdCdTRQQmg3VEtNZzNSR0FNbG9NWkxUTVJfdW01ZlNDdUgyczV5b1V4WjBxY0FiZFdWVFNsZ0ROdmFWcVc3SGN0LVlZNmZFeEljdm1faGxoWElzM0VpcDNaMjhQMG1FdEdGME15ejROQlRwN1p1cE0yRGFSVWNaY0hIOURyaG04NG9meS14NUU0VzN0NHdLTElsZXFF?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of MannKind Corporation \u2013 NASDAQ:MNKD", "summary": "This article provides financial information for MannKind Corporation (NASDAQ: MNKD), specifically its enterprise value to EBIT forward ratio. It's concise and is part of a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-MNKD/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:09:35", "published_display": "27 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MannKind Corporation \u2013 NASDAQ:MNKD", "summary": "This article provides financial data for MannKind Corporation (NASDAQ: MNKD), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial snapshot from a trading platform, indicating the current market status and offering various ", "url": "https://www.tradingview.com/symbols/NASDAQ-MNKD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:28", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MannKind Corporation \u2013 BX:NNFN", "summary": "This page provides financial information for MannKind Corporation (BX:NNFN) on BX Swiss, specifically focusing on its forward price-to-earnings ratio. The market is currently closed with no trades. The content highlights a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/BX-NNFN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:40:38", "published_display": "26 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MannKind Corporation \u2013 NASDAQ:MNKD", "summary": "This article provides financial snapshot of MannKind Corporation (NASDAQ: MNKD) focusing on its enterprise value to revenue forward. It appears to be an excerpt or a data point from a larger financial analysis platform, likely TradingView, indicating that the market for MNKD is c", "url": "https://www.tradingview.com/symbols/NASDAQ-MNKD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:40:38", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind shares, Friday focus on the U.S. listing", "summary": "MannKind Corp (MNKD) shares are closing the week with a focus on their U.S. listing on Nasdaq, with the article discussing the broader U.S. market context and the company's inhaled therapy business. Despite a mixed U.S. market session, attention remains on healthcare names like M", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mannkind-shares-friday-focus-on-the-u-s-listing/69635850", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T20:40:38", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corporation Actuals & Estimates (BX:NNFN)", "summary": "This article provides an overview of MannKind Corporation's financial actuals and estimates, including its stock ticker (NNFN on BX Swiss), analyst forecasts, historical price dynamics, market capitalization, and upcoming earnings date. It also details the company's latest revenu", "url": "https://www.tradingview.com/symbols/BX-NNFN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:28", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of MannKind Corp (MNKD), noting its current price momentum score and suggesting suitability for range-bound swing trading as it trades between resistance at $4.17 and support at $3.41. It presents a summary of technical indicators and mo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/technical", "source_name": "TradingKey", "published_at": "2026-06-25T00:39:37", "published_display": "25 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Afrezza Pediatric Trial Grant Might Change The Case For Investing In MannKind (MNKD)", "summary": "MannKind Corporation received a grant from Breakthrough T1D for its INHALE-1 clinical study of Afrezza in pediatric type 1 diabetes patients. This funding, combined with recent FDA approval for children, de-risks pediatric Afrezza development and presents a growth opportunity. In", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T16:09:43", "published_display": "24 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza\u00ae in Youth with Newly-Diagnosed T1D", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mannkind-awarded-breakthrough-t1d-grant-130000457.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T13:00:00+00:00", "published_display": "23 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakthrough T1D backs MannKind\u2019s pediatric Afrezza trial", "summary": "MannKind Corporation has received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial for Afrezza in pediatric patients newly diagnosed with type 1 diabetes. This multi-center study will evaluate the safety and efficacy of Afrezza, an ultra rapid-acting inhaled", "url": "https://www.stocktitan.net/news/MNKD/mann-kind-awarded-breakthrough-t1d-grant-to-support-advancement-of-yladca6h7f0v.html", "source_name": "Stock Titan", "published_at": "2026-06-23T12:40:04", "published_display": "23 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Awarded Breakthrough T1D Grant to Support Accessibility", "summary": "MannKind Corporation has been awarded a grant from Breakthrough T1D (formerly JDRF) to support its INHALE-1ST clinical study. This study evaluates the use of Afrezza (insulin human) Inhalation Powder in newly-diagnosed pediatric patients with type 1 diabetes. The grant reinforces", "url": "https://www.globenewswire.com/news-release/2026/06/23/3316025/29517/en/mannkind-awarded-breakthrough-t1d-grant-to-support-advancement-of-inhale-1st-pediatric-trial-of-afrezza-in-youth-with-newly-diagnosed-t1d.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T09:00:00", "published_display": "23 Jun 2026 09:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for MannKind Corp (MNKD) based on business segments and regional contributions. For FY2023, product sales accounted for 62.05% ($216.52M), royalties for 36.71% ($128.12M), and services for 1.24% ($4.33M) of the total revenue. All reported", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:31", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Institutional Confidence", "summary": "MannKind Corp (MNKD) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 17.51% quarter-over-quarter to 67.28%. James Simons is noted as the largest institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:13", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why MannKind (MNKD) Is Up 8.4% After New Afrezza Pediatric Approval And ADA Data Release", "summary": "MannKind Corporation (MNKD) saw an 8.4% increase after announcing new clinical data for its inhaled insulin, Afrezza, and FUROSCIX at the American Diabetes Association\u2019s 2026 Scientific Sessions, following the U.S. FDA's May 2026 approval of Afrezza for pediatric use. This data a", "url": "https://www.sahmcapital.com/news/content/why-mannkind-mnkd-is-up-84-after-new-afrezza-pediatric-approval-and-ada-data-release-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-17T23:10:40", "published_display": "17 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "MannKind Corp (MNKD) has a current financial score of 7.73, ranking 86th out of 389 in the Biotechnology & Medical Research industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue increased by 15.08% year-over-year to $90.1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:38", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "MannKind Corp (MNKD) has an earnings forecast score of 8.25, ranking 143 out of 388 in its industry, with an average analyst price target of $9.00. Based on 8 analysts, the stock receives a \"Buy\" rating with a target upside of 96.22%. The company's expected revenue for the next q", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T22:11:10", "published_display": "17 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Calls MannKind Corporation (MNKD)\u2019s Commercial Potential a \u201cShow-Me Story\u201d", "summary": "Wells Fargo recently raised its price target on MannKind Corporation (MNKD) to $11 from $10, reiterating an Overweight rating, following the FDA's approval of Afrezza for pediatric patients. This approval, expanding Afrezza's use to children aged 6 and older with type 1 and type ", "url": "https://sg.finance.yahoo.com/news/wells-fargo-calls-mannkind-corporation-153105791.html", "source_name": "Market source", "published_at": "2026-06-13T15:38:55", "published_display": "13 Jun 2026 15:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "7 Hidden Penny Stocks to Invest In", "summary": "This article highlights MannKind Corporation (NASDAQ:MNKD) as one of seven hidden penny stocks to consider. The biopharmaceutical company recently received FDA approval for its Afrezza Inhalation Powder in pediatric patients and has potential for significant development milestone", "url": "https://www.insidermonkey.com/blog/7-hidden-penny-stocks-to-invest-in-1779599/2/", "source_name": "Insider Monkey", "published_at": "2026-06-12T19:08:57", "published_display": "12 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data", "summary": "MannKind (MNKD) is gaining investor attention after recent positive clinical data for Afrezza and FUROSCIX, alongside pediatric FDA approval for Afrezza. Despite a recent 35.38% share price rebound over 90 days, the year-to-date return is still down 33.04%. The company is conside", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mannkind-mnkd-stock-valuation-afrezza-021338140.html", "source_name": "Market source", "published_at": "2026-06-12T02:13:00", "published_display": "12 Jun 2026 02:13", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind gains FDA nod to expand inhaled insulin for children", "summary": "MannKind Corporation has received FDA approval to expand the label for its Afrezza inhaled insulin. This expansion now includes children and adolescents aged four to 17 with diabetes, making Afrezza the first inhaled insulin option for a pediatric population. The company plans to", "url": "https://www.msn.com/en-us/health/other/mannkind-gains-fda-nod-to-expand-inhaled-insulin-for-children/ar-AA24n960?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-11T22:40:41", "published_display": "11 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Afrezza Pediatric Approval And New Data Shift MannKind\u2019s (MNKD) Technosphere Platform Investment Narrative?", "summary": "MannKind (MNKD) recently announced FDA approval of Afrezza for children aged 6 and older, alongside new clinical data for Afrezza and FUROSCIX. This progress, including the advancement of nintedanib DPI into Phase 2 trials for idiopathic pulmonary fibrosis, could significantly al", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/should-afrezza-pediatric-approval-and-new-data-shift-mannkin", "source_name": "Simply Wall Street", "published_at": "2026-06-09T08:09:55", "published_display": "09 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly", "summary": "The American Diabetes Association (ADA) conference 2026 featured significant readouts in type 1 and type 2 diabetes. Roche's acmopatide showed promise in T1D by reducing A1C levels and insulin requirements while aiding weight loss. MannKind's inhaled insulin Afrezza received FDA ", "url": "https://www.yahoo.com/news/science/articles/ada26-t1-t2-diabetes-readouts-151922645.html", "source_name": "Yahoo", "published_at": "2026-06-09T06:39:04", "published_display": "09 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Says He Blessed MannKind as a Speculation Only", "summary": "Jim Cramer commented on MannKind Corporation (NASDAQ: MNKD) during a Mad Money lightning round, approving it solely as a \"speculation\" stock. He emphasized that investors should balance speculative plays like MannKind with more earnings-oriented investments. MannKind is a biophar", "url": "https://www.insidermonkey.com/blog/jim-cramer-says-he-blessed-mannkind-as-a-speculation-only-1777332/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-08T15:10:12", "published_display": "08 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MannKind (MNKD) Now An Opportunity After A 39% Year To Date Share Price Decline?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market\u2019s Appetite for New Supply", "summary": "Jim Cramer highlighted 16 stocks, including Quantinuum, indicating the market's strong appetite for new supply. Among the mentioned stocks is MannKind Corporation (NASDAQ:MNKD), which Cramer described as a \"total speculation\" for investors looking to balance their portfolios with", "url": "https://www.insidermonkey.com/blog/jim-cramer-highlighted-16-stocks-including-quantinuum-and-the-markets-appetite-for-new-supply-1776233/3", "source_name": "Insider Monkey", "published_at": "2026-06-06T12:49:00", "published_display": "06 Jun 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Data at ADA 2026 Highlights Key Findings from Clinical and Real\u2011World Studies of MannKind\u2019s Afrezza\u00ae (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/data-ada-2026-highlights-key-233500456.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T23:35:00+00:00", "published_display": "05 Jun 2026 23:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhaled insulin data explore options for kids, pregnancy and pump users", "summary": "MannKind (Nasdaq: MNKD) announced new data for its inhaled insulin, Afrezza, and FUROSCIX, presented at the ADA 2026 Scientific Sessions. The findings highlight Afrezza's benefits for pediatric patients, gestational diabetes, and compatibility with automated insulin delivery syst", "url": "https://www.stocktitan.net/news/MNKD/data-at-ada-2026-highlights-key-findings-from-clinical-and-real-le4t18oo7f78.html", "source_name": "Stock Titan", "published_at": "2026-06-05T23:10:12", "published_display": "05 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mannkind-mnkd-advances-clinical-trials-215646700.html", "source_name": "Insider Monkey", "published_at": "2026-06-05T21:56:46+00:00", "published_display": "05 Jun 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news", "summary": "MannKind Corp shares continue to trade in the lower single digits on Nasdaq, with recent FDA and partnership developments bringing valuation ratios into focus. The company has moved into profitability in the last twelve months, supported by inhaled therapies and collaborations, y", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mannkind-corp-stock-us5638651064-focus-on-valuation-metrics-after/69490106", "source_name": "AD HOC NEWS", "published_at": "2026-06-05T22:26:22", "published_display": "05 Jun 2026 22:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mannkind-completes-patient-randomization-phase-110409434.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:04:09+00:00", "published_display": "03 Jun 2026 11:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind tests inhaled IPF drug in global trial, first data Q3 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOLUFDN1lmczFLRG9iYjVRLU1lZV9NX044MmM3UWtUTTBoNm5hSzRfUEFoUmNsZ05CWnltM3ZSWUs0RW5LSEpHbmxXQzZNWWRpZFN3WGc2Q3JUSXlvN2N4bzJ6UVlWaVc3QTBZcWVtM0owT3JVczVTTjFya1VEZWU3RmVEeWtEUHQybnpqT3JocnlGYUd2SGQweHJ0TXBuMzNtbFZRTmpMZm0xVkdKNEFTQi02RDBvcTYwZl80?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNSk1CQnpzalhsUGZSY0JFOXBhN3REczcxZkRRSEFybko0dDdPVEVBRm1KelJoZ0ZNM29xSHU3YWFDTy05RW40R2sxQlo5dXVtLWd3S2ZMQzRuYS00T3pJM0pxbHZlT1R0QTFtb3RZNFBwVVRHUkFCRmpPTFRmaHpFc1BkWkplR1kzRzY1eGdHUWpITThleU12RzJuYkZzc3JIR2RpMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPXzI3eDlDc1Frb0JnREFnd3ZyaGJ0bUJ1R2thQ2pXMGxBSk8tcjFNWXRHc21veDRpNlV3cGZJRHdqc2V0aEplcDZjTFlrZGtyVW5TUUhRdG9MNHh4SGxtZUtzcUxseGJNYmt5UlhDekVadU5KaWxZTXdyekpQckRiYlFSa29ST2NIdjNQWnhGMWllTEVwYk9vdGZudVNKVzdabjg4bDUwSlB4MnpWZy1aX21acjNTUWdmNjV3MGIyZWNkY1Nr?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial Relief - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPcUVKS29pSUFNSkF6X2piTEdYazl5TEoyX3BEQ05hVHZkbHVyY0d4TWpnYXZlYmIwa3RwWWtuRVpBa0NtSlBpZzRLMU1oM0NXcEp3OERra1ZjWk16cUdHLU9LS2ptMFc0Nm5HeHdHYnlPN3dYSGN6LUtTSmQ2VUpSVENCNmdIWnlRdHhhVUFBUExoMmpTdWR5SUJFMA?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves MannKind's inhaled insulin for children", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNS1JEaHBMcW95MzZ2WnBMTWVoVE13UUpvNVFDZndIMGEzbU9xTDA2Q25RVzlKVzZhVXYycGswNTI3Ry1YR212TEhNdzFEUzhtWFNmM0FYZ2VEVk04SkcxVHcxQlAzOGNCSC1JRUM2OXpyQTFzVUFONV85N0tXVEZuU2dLUlpTWkhLNm5CU2ZNZjlQSFlwOWVheFgxOG1ZZHEwUUU4MEFRLUd2aVBsMFZ0akVmUlFMQ1ZjZE52aFFtYw?oc=5", "source_name": "Reuters", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): focus on Afrezza growth and partnership pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSXpJUEowR2x0QXVzSWhNZl9QNmhaREo2TXFHWU53Z0tzdWNRbnVsY0U4U0NEWklEQndJS2xlOU9uV0FRcjZTdVhycDhIUTBGVlkxQVNpeFJFN0NUMVg3NUl2d29uSjc5dmEwZFB4ZUhoYkNtaEdjdXNMdXhLRWNwb2FqWXp4Vk5VTTJtYnY2N2FTX3FwakZfVmZzRkxZT3RHcWl6TjVpd1l2OHdOeExGSHZVajJSNWlBWHBV?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPU2ZrVGpidnZ2Y1U4LTU4NFptSzItaDZ1YjFSaU0wSlB3cURNS2ZIMHBRYkFPQ3pBSlozdmxjbGFMMG1JZEliQUs1NzJUbkh6aTFNOW1hcURZVnM3MGh4MHZGZ0JudGQzdzZpRUlJUkFlZFhaOWdRNWwtSFROdEZ6a29ORFJXWW1COXlhTWpmU3NrMnFpLUlMdnRB?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "State Street (NASDAQ: MNKD) holds 18.68M shares, 6.1% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNM1IyY3dOcDBXSjdqT1VxUlJwYjdEblZic05XQkkzbjFoOGFKV1J3NHQtbGc4RHNxX05KSWp3Y1pJRm1WYXYwSmRrUklpQ29Janl0dVQzMmVzal9paWNJN3RoNDhtUnk1QmhCVlN1OVFxdUtyTFB1dWlZSTB2dG1fMmtJZXgzZk5PU01FWlJSTEtOVjI0dGM2UDhKemhwVjYwVzJuRHZWeFdfU3AzUGFuYTg4dHNfSFpfbU02Xw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): Q1 2026 earnings miss on EPS, revenue up 15%", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQblZKYk9UdGZvR2FsZ2V6akhIZ0N6Skx4MUdIV3FXaFNKRDE1c0RMQ0NmWHBSbzlIbDRELTRpUDYzXzd3a3J0eWIybWJIWE16OW9WV3I4MGxjT2l5YWlMVS0zeWxIMlRIQ29oNUlmSkp3UFBobVNGSnZCS2lFU0ZUNFRVMmZuUGpjRU96aVlPUWJEOHR3N0JuMXVuVU9aWU8tcXlQaUkwLVZJOF92S0hNX2tXd0ozR18wNnRCU1gyYzcxM1RTQkln?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQMWtSVS1WaXZBcWJUX0ZuN1Q4XzdIQWM4RWdUeTdtc3hWY3NnUnF6ajV2TGlBNWNFeUJVT2pHNC0wSmt1aWdOdlRtaDJtUHdJNkpxUUtxd1owQ0tlMDg3cThGQlA5WW56bVlhbms2LURqZ1hya2VwNGF6T1NackEtbmsyU2Q1SEdCUzVqcnVZY1c0Z0JnbkE?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MannKind stock drops after Q1 2026 miss (MNKD:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOX1dLUHc5bk5wZzJjVHJkQ3RHV2dBMDlGMlRtelhmQVN3OExTeWZ3LUg0a0s2MnZneEcwQl9LQ3lsS05uZjdyQ185aW5yaC04WkNnelBub01QTEw5NkE5S1AzSU81Ukdoc0ZhTExBMkRmMkhCWDBPcnprajhjYU1YV1NEUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind stock surges on United Therapeutics partnership deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWEdUSkFDa3RRbWZYc3ZTelJ5dk8yYVhkM0ZSV0VQNnhheWsyVEl5eS1SUDhzMXg5dlAxZVJPLUk4Z0c2WDlRdnFON2hkM19rSTl3OTJKczFhb2Q1WVpIS21Pb0gxVk1PVUZaZXNSODkxT2cxeDEzTGZxN09YcXhXWE13VGtWdFppbk5UcjNCUlZxYktFUThCV3lVNlliN1M0X3hOX3NFbjNVVW1rZVZXbmFSWW9ETVJ4c3hRNk5sVDI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPdE9LWFRBRV83YTd3X2g5OEhWRFNvT0NsLWNPY1o2VE9fS0xiNHdlbnEzdjZvbjF3d1d6WFZGUXM1MHFmVk5vWnY5QlRMbTcxNnRObjAxdG9VS1RUcTlCQmtoWktCV0NocG1yX3lPT1pxcm02bEpkRXRSUVdGVnhPU213cXVQMXNEVmNJanBpUWN2T1RtcHc4aXpB?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks Facing FDA Decision In May\u2014MannKind (MNKD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPblNOZlA2T2pvZUlrV3J2WlAxYTFrcWpEUkFQbTVXWGhRWjlZQldCdzVJakR2ZzFodF9pMTFTaUt6YmtUMVY4UnJOOFp0bm1OSm9WWHl6R19IekswRkNSd2tib2xCNHJCQkJiYlhfSVNQSlFodHQtLTBCR0V6ZXB0MUk0Q3FhSkF6OUJ0WjJveFlCOVNGekhHTkxPYy1mS3RTTmw0YWwxNEJBbUs4MWhTd0hOaEpHaVVLMk1IRA?oc=5", "source_name": "Forbes", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPOGhUd3pXZERualk4N0pCQXpIZVBTR3NINTFQNGZYN0I2ZWFXS1pVUjJhclZHQmpIRThELUJlc1JzQ0ozZGRHYjQ2U3JEaEowUmJ4RlZVd2N3UG5zT1JSbEltLXNhQlRkblF2RjNDaGw2RThZUnE0UDhwOEEzV01jTkJVajNoZ0p3ZVVkLWEzNDNLUXJwZGlfYVFvRkN5aEFxaE9LSnE5aHQ1Y0MwT0E?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOYXRhNDExdGRiQlZDTndJa3ZVeDNrSEtzbjdCeXpUS2FoR215eEtJb0xCY0dERVlzdndfdC0xNTRTcE5RY2lZeFNDcndVNWtXNzd2UU16NDEtRlo0anF6Nzl1VGpweXBOeU8yZ2FzenpQcUZBX2FSNl9ZR1BuTEhwZmNkcmw2cnlSV2lPU2g2SHFESi1tNnFPVEVPZ3lYOURaZlE?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNbFV0VTBKRllmY3RSZEJJVmZOdWYtMXpUOUVRLUEwejJJRjNtdmFVX3VfRzNVOGZTOU1QTUdLNHRjYzBFS2FVNF90eHpUQklJdXRHNlZaeW1OY19zdlc3NlBjXzlNbVBoME9YanRfN0JoN3czTnFoY254ZUV2bUpZNHZYN09SNllyZDcxU05YdExyYlQ0NWk3bWpnYnJhdFU?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQX1djSXdqZGIyRm9BenF1N2xPN3NkNjZkSl9WZ1VRTzZuZ21GMy1vN1hCUXdXVWVqODZrQWEzUFc1Z3JlYUJnVGNzblRsN2lvNy04VGlLamYtTDJoeTI5djZKNWprNkN0Y0F3WkdRcDJDbkZEZjJIOGZSM2NLMzZGaS1fNE5IWGpRMEtDakZkYWh0T2pQeWNlclJ3QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T17:29:21+00:00", "published_display": "09 Jul 2026 17:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp looks beyond inhaled insulin as pipeline ambitions grow", "summary": "MannKind Corp is expanding its pipeline beyond its inhaled insulin product, Afrezza, by seeking new therapeutic applications for its Technosphere drug-delivery platform. While Afrezza remains the commercial foundation, the company is exploring other indications like pulmonary art", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mannkind-corp-looks-beyond-inhaled-insulin-as-pipeline-ambitions-grow/69715094", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:41:48", "published_display": "07 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Receives a Grant from Breakthrough T1D", "summary": "MannKind Corporation (MNKD) received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial, which evaluates inhaled insulin in newly diagnosed pediatric patients with type 1 diabetes. This grant provides external validation for Afrezza, MannKind's inhaled insulin", "url": "https://www.insidermonkey.com/blog/mannkind-mnkd-receives-a-grant-from-breakthrough-t1d-1794185/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:09:35", "published_display": "03 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Wins Breakthrough T1D Grant, Is The Stock Still 11% Undervalued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Stock Plummets After Partner United Therapeutics Unveils New \u2018Category Killer Product\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQX2cyYnVaVExIWG1QRjNUMVdkQ1Y2eW5VRzJ2WE13ckJXenVLV3F6ZFR4SEcyR2lsc2pveERra0ZxV3ZUUDZTNndrcXZ3aXFGenRmUkZacnM2THRPaTZ2dXdQR3k5ZDh6Q3dpUEV5cll0cUw3c1o2bTZmX2hvXzJkZEhaeDAxYV9id2hodTlQUUt2VWVtNzdMbzhKSFJTd3JXSVNwVGVRZWYxR0Q3aTJwT2ZrYThYU1ZvV2dIRlgzaXhGSzk5dndObW0wclU5QW9zQW5CeDhqQ0JuSm16Wlk5QlZ6aVdVdW0zNVh5MTJn?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-03T03:21:09+00:00", "published_display": "03 Jul 2026 03:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MannKind Corporation (MNKD) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQeE4zZ0lYdFdCdTRQQmg3VEtNZzNSR0FNbG9NWkxUTVJfdW01ZlNDdUgyczV5b1V4WjBxY0FiZFdWVFNsZ0ROdmFWcVc3SGN0LVlZNmZFeEljdm1faGxoWElzM0VpcDNaMjhQMG1FdEdGME15ejROQlRwN1p1cE0yRGFSVWNaY0hIOURyaG04NG9meS14NUU0VzN0NHdLTElsZXFF?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of MannKind Corporation \u2013 NASDAQ:MNKD", "summary": "This article provides financial information for MannKind Corporation (NASDAQ: MNKD), specifically its enterprise value to EBIT forward ratio. It's concise and is part of a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-MNKD/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:09:35", "published_display": "27 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MannKind Corporation \u2013 NASDAQ:MNKD", "summary": "This article provides financial data for MannKind Corporation (NASDAQ: MNKD), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial snapshot from a trading platform, indicating the current market status and offering various ", "url": "https://www.tradingview.com/symbols/NASDAQ-MNKD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:28", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of MannKind Corporation \u2013 BX:NNFN", "summary": "This page provides financial information for MannKind Corporation (BX:NNFN) on BX Swiss, specifically focusing on its forward price-to-earnings ratio. The market is currently closed with no trades. The content highlights a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/BX-NNFN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:40:38", "published_display": "26 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MannKind Corporation \u2013 NASDAQ:MNKD", "summary": "This article provides financial snapshot of MannKind Corporation (NASDAQ: MNKD) focusing on its enterprise value to revenue forward. It appears to be an excerpt or a data point from a larger financial analysis platform, likely TradingView, indicating that the market for MNKD is c", "url": "https://www.tradingview.com/symbols/NASDAQ-MNKD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:40:38", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind shares, Friday focus on the U.S. listing", "summary": "MannKind Corp (MNKD) shares are closing the week with a focus on their U.S. listing on Nasdaq, with the article discussing the broader U.S. market context and the company's inhaled therapy business. Despite a mixed U.S. market session, attention remains on healthcare names like M", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mannkind-shares-friday-focus-on-the-u-s-listing/69635850", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T20:40:38", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corporation Actuals & Estimates (BX:NNFN)", "summary": "This article provides an overview of MannKind Corporation's financial actuals and estimates, including its stock ticker (NNFN on BX Swiss), analyst forecasts, historical price dynamics, market capitalization, and upcoming earnings date. It also details the company's latest revenu", "url": "https://www.tradingview.com/symbols/BX-NNFN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:28", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of MannKind Corp (MNKD), noting its current price momentum score and suggesting suitability for range-bound swing trading as it trades between resistance at $4.17 and support at $3.41. It presents a summary of technical indicators and mo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/technical", "source_name": "TradingKey", "published_at": "2026-06-25T00:39:37", "published_display": "25 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Afrezza Pediatric Trial Grant Might Change The Case For Investing In MannKind (MNKD)", "summary": "MannKind Corporation received a grant from Breakthrough T1D for its INHALE-1 clinical study of Afrezza in pediatric type 1 diabetes patients. This funding, combined with recent FDA approval for children, de-risks pediatric Afrezza development and presents a growth opportunity. In", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T16:09:43", "published_display": "24 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza\u00ae in Youth with Newly-Diagnosed T1D", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mannkind-awarded-breakthrough-t1d-grant-130000457.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T13:00:00+00:00", "published_display": "23 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakthrough T1D backs MannKind\u2019s pediatric Afrezza trial", "summary": "MannKind Corporation has received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial for Afrezza in pediatric patients newly diagnosed with type 1 diabetes. This multi-center study will evaluate the safety and efficacy of Afrezza, an ultra rapid-acting inhaled", "url": "https://www.stocktitan.net/news/MNKD/mann-kind-awarded-breakthrough-t1d-grant-to-support-advancement-of-yladca6h7f0v.html", "source_name": "Stock Titan", "published_at": "2026-06-23T12:40:04", "published_display": "23 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Awarded Breakthrough T1D Grant to Support Accessibility", "summary": "MannKind Corporation has been awarded a grant from Breakthrough T1D (formerly JDRF) to support its INHALE-1ST clinical study. This study evaluates the use of Afrezza (insulin human) Inhalation Powder in newly-diagnosed pediatric patients with type 1 diabetes. The grant reinforces", "url": "https://www.globenewswire.com/news-release/2026/06/23/3316025/29517/en/mannkind-awarded-breakthrough-t1d-grant-to-support-advancement-of-inhale-1st-pediatric-trial-of-afrezza-in-youth-with-newly-diagnosed-t1d.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T09:00:00", "published_display": "23 Jun 2026 09:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for MannKind Corp (MNKD) based on business segments and regional contributions. For FY2023, product sales accounted for 62.05% ($216.52M), royalties for 36.71% ($128.12M), and services for 1.24% ($4.33M) of the total revenue. All reported", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:31", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Institutional Confidence", "summary": "MannKind Corp (MNKD) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 17.51% quarter-over-quarter to 67.28%. James Simons is noted as the largest institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:13", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why MannKind (MNKD) Is Up 8.4% After New Afrezza Pediatric Approval And ADA Data Release", "summary": "MannKind Corporation (MNKD) saw an 8.4% increase after announcing new clinical data for its inhaled insulin, Afrezza, and FUROSCIX at the American Diabetes Association\u2019s 2026 Scientific Sessions, following the U.S. FDA's May 2026 approval of Afrezza for pediatric use. This data a", "url": "https://www.sahmcapital.com/news/content/why-mannkind-mnkd-is-up-84-after-new-afrezza-pediatric-approval-and-ada-data-release-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-17T23:10:40", "published_display": "17 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "MannKind Corp (MNKD) has a current financial score of 7.73, ranking 86th out of 389 in the Biotechnology & Medical Research industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue increased by 15.08% year-over-year to $90.1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:38", "published_display": "17 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "MannKind Corp (MNKD) has an earnings forecast score of 8.25, ranking 143 out of 388 in its industry, with an average analyst price target of $9.00. Based on 8 analysts, the stock receives a \"Buy\" rating with a target upside of 96.22%. The company's expected revenue for the next q", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mnkd/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T22:11:10", "published_display": "17 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Calls MannKind Corporation (MNKD)\u2019s Commercial Potential a \u201cShow-Me Story\u201d", "summary": "Wells Fargo recently raised its price target on MannKind Corporation (MNKD) to $11 from $10, reiterating an Overweight rating, following the FDA's approval of Afrezza for pediatric patients. This approval, expanding Afrezza's use to children aged 6 and older with type 1 and type ", "url": "https://sg.finance.yahoo.com/news/wells-fargo-calls-mannkind-corporation-153105791.html", "source_name": "Market source", "published_at": "2026-06-13T15:38:55", "published_display": "13 Jun 2026 15:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "7 Hidden Penny Stocks to Invest In", "summary": "This article highlights MannKind Corporation (NASDAQ:MNKD) as one of seven hidden penny stocks to consider. The biopharmaceutical company recently received FDA approval for its Afrezza Inhalation Powder in pediatric patients and has potential for significant development milestone", "url": "https://www.insidermonkey.com/blog/7-hidden-penny-stocks-to-invest-in-1779599/2/", "source_name": "Insider Monkey", "published_at": "2026-06-12T19:08:57", "published_display": "12 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data", "summary": "MannKind (MNKD) is gaining investor attention after recent positive clinical data for Afrezza and FUROSCIX, alongside pediatric FDA approval for Afrezza. Despite a recent 35.38% share price rebound over 90 days, the year-to-date return is still down 33.04%. The company is conside", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mannkind-mnkd-stock-valuation-afrezza-021338140.html", "source_name": "Market source", "published_at": "2026-06-12T02:13:00", "published_display": "12 Jun 2026 02:13", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind gains FDA nod to expand inhaled insulin for children", "summary": "MannKind Corporation has received FDA approval to expand the label for its Afrezza inhaled insulin. This expansion now includes children and adolescents aged four to 17 with diabetes, making Afrezza the first inhaled insulin option for a pediatric population. The company plans to", "url": "https://www.msn.com/en-us/health/other/mannkind-gains-fda-nod-to-expand-inhaled-insulin-for-children/ar-AA24n960?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-11T22:40:41", "published_display": "11 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Afrezza Pediatric Approval And New Data Shift MannKind\u2019s (MNKD) Technosphere Platform Investment Narrative?", "summary": "MannKind (MNKD) recently announced FDA approval of Afrezza for children aged 6 and older, alongside new clinical data for Afrezza and FUROSCIX. This progress, including the advancement of nintedanib DPI into Phase 2 trials for idiopathic pulmonary fibrosis, could significantly al", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/should-afrezza-pediatric-approval-and-new-data-shift-mannkin", "source_name": "Simply Wall Street", "published_at": "2026-06-09T08:09:55", "published_display": "09 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly", "summary": "The American Diabetes Association (ADA) conference 2026 featured significant readouts in type 1 and type 2 diabetes. Roche's acmopatide showed promise in T1D by reducing A1C levels and insulin requirements while aiding weight loss. MannKind's inhaled insulin Afrezza received FDA ", "url": "https://www.yahoo.com/news/science/articles/ada26-t1-t2-diabetes-readouts-151922645.html", "source_name": "Yahoo", "published_at": "2026-06-09T06:39:04", "published_display": "09 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Says He Blessed MannKind as a Speculation Only", "summary": "Jim Cramer commented on MannKind Corporation (NASDAQ: MNKD) during a Mad Money lightning round, approving it solely as a \"speculation\" stock. He emphasized that investors should balance speculative plays like MannKind with more earnings-oriented investments. MannKind is a biophar", "url": "https://www.insidermonkey.com/blog/jim-cramer-says-he-blessed-mannkind-as-a-speculation-only-1777332/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-08T15:10:12", "published_display": "08 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MannKind (MNKD) Now An Opportunity After A 39% Year To Date Share Price Decline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNbDF5bVRBaEh6Zm5xWmF1MC1vbEc1T01wVXNZVGZtX2NvWVo4Y0o2SHZKbTF3aDV1c2g4S1F1cDdwVjVFT01pVVZDOVI4SmtqZ1FpVU1HSmEzbXRDdk01V3RDZllWMUJEUmZiX3hISmpZa0Fkc3QxSWczNk5DQjh6Q00wZWNPRFVKbGJudHQtaWxJdEk1NGN6LTAyMGsxT1hxcGVaLU50NVJyXzBJdldWOVBOYVpqQzdIWkc0Mm1WN0J6Znh6TDg4SUNyeVgxX1QwcmttQm5za1TSAd4BQVVfeXFMUHkyd3l1NHBnRElTUjZPS2JfMWltWG03cVAyR0ktRmZzd0ZDcHF6UGROcTdCcTVMV2xoa3g2dTdIMlAxN2dSc0hKM0RScnR1M2otZVdOazhyY1plN3J1bXR1ZGgzTkdJdklRTFpQTE5zLXpmeEZRSnNPQXc5X1V3aEVGclBnYl9Oc0R3dXVrVjM0THZnbml3Z290aERXSmJxUGI1MTJZZlU1TjZGWS1WNDdWWGd6Z3VsY214XzVPcWFBVFY1NWJ2QjN3blZMMVdLc1k2SFJlVmZtWkM3WWh3?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market\u2019s Appetite for New Supply", "summary": "Jim Cramer highlighted 16 stocks, including Quantinuum, indicating the market's strong appetite for new supply. Among the mentioned stocks is MannKind Corporation (NASDAQ:MNKD), which Cramer described as a \"total speculation\" for investors looking to balance their portfolios with", "url": "https://www.insidermonkey.com/blog/jim-cramer-highlighted-16-stocks-including-quantinuum-and-the-markets-appetite-for-new-supply-1776233/3", "source_name": "Insider Monkey", "published_at": "2026-06-06T12:49:00", "published_display": "06 Jun 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Data at ADA 2026 Highlights Key Findings from Clinical and Real\u2011World Studies of MannKind\u2019s Afrezza\u00ae (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/data-ada-2026-highlights-key-233500456.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T23:35:00+00:00", "published_display": "05 Jun 2026 23:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhaled insulin data explore options for kids, pregnancy and pump users", "summary": "MannKind (Nasdaq: MNKD) announced new data for its inhaled insulin, Afrezza, and FUROSCIX, presented at the ADA 2026 Scientific Sessions. The findings highlight Afrezza's benefits for pediatric patients, gestational diabetes, and compatibility with automated insulin delivery syst", "url": "https://www.stocktitan.net/news/MNKD/data-at-ada-2026-highlights-key-findings-from-clinical-and-real-le4t18oo7f78.html", "source_name": "Stock Titan", "published_at": "2026-06-05T23:10:12", "published_display": "05 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mannkind-mnkd-advances-clinical-trials-215646700.html", "source_name": "Insider Monkey", "published_at": "2026-06-05T21:56:46+00:00", "published_display": "05 Jun 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news", "summary": "MannKind Corp shares continue to trade in the lower single digits on Nasdaq, with recent FDA and partnership developments bringing valuation ratios into focus. The company has moved into profitability in the last twelve months, supported by inhaled therapies and collaborations, y", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mannkind-corp-stock-us5638651064-focus-on-valuation-metrics-after/69490106", "source_name": "AD HOC NEWS", "published_at": "2026-06-05T22:26:22", "published_display": "05 Jun 2026 22:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Completes Patient Randomization in Phase 1b Idiopathic Pulmonary Fibrosis Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mannkind-completes-patient-randomization-phase-110409434.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:04:09+00:00", "published_display": "03 Jun 2026 11:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind tests inhaled IPF drug in global trial, first data Q3 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOLUFDN1lmczFLRG9iYjVRLU1lZV9NX044MmM3UWtUTTBoNm5hSzRfUEFoUmNsZ05CWnltM3ZSWUs0RW5LSEpHbmxXQzZNWWRpZFN3WGc2Q3JUSXlvN2N4bzJ6UVlWaVc3QTBZcWVtM0owT3JVczVTTjFya1VEZWU3RmVEeWtEUHQybnpqT3JocnlGYUd2SGQweHJ0TXBuMzNtbFZRTmpMZm0xVkdKNEFTQi02RDBvcTYwZl80?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNSk1CQnpzalhsUGZSY0JFOXBhN3REczcxZkRRSEFybko0dDdPVEVBRm1KelJoZ0ZNM29xSHU3YWFDTy05RW40R2sxQlo5dXVtLWd3S2ZMQzRuYS00T3pJM0pxbHZlT1R0QTFtb3RZNFBwVVRHUkFCRmpPTFRmaHpFc1BkWkplR1kzRzY1eGdHUWpITThleU12RzJuYkZzc3JIR2RpMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPXzI3eDlDc1Frb0JnREFnd3ZyaGJ0bUJ1R2thQ2pXMGxBSk8tcjFNWXRHc21veDRpNlV3cGZJRHdqc2V0aEplcDZjTFlrZGtyVW5TUUhRdG9MNHh4SGxtZUtzcUxseGJNYmt5UlhDekVadU5KaWxZTXdyekpQckRiYlFSa29ST2NIdjNQWnhGMWllTEVwYk9vdGZudVNKVzdabjg4bDUwSlB4MnpWZy1aX21acjNTUWdmNjV3MGIyZWNkY1Nr?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial Relief - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPcUVKS29pSUFNSkF6X2piTEdYazl5TEoyX3BEQ05hVHZkbHVyY0d4TWpnYXZlYmIwa3RwWWtuRVpBa0NtSlBpZzRLMU1oM0NXcEp3OERra1ZjWk16cUdHLU9LS2ptMFc0Nm5HeHdHYnlPN3dYSGN6LUtTSmQ2VUpSVENCNmdIWnlRdHhhVUFBUExoMmpTdWR5SUJFMA?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves MannKind's inhaled insulin for children", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNS1JEaHBMcW95MzZ2WnBMTWVoVE13UUpvNVFDZndIMGEzbU9xTDA2Q25RVzlKVzZhVXYycGswNTI3Ry1YR212TEhNdzFEUzhtWFNmM0FYZ2VEVk04SkcxVHcxQlAzOGNCSC1JRUM2OXpyQTFzVUFONV85N0tXVEZuU2dLUlpTWkhLNm5CU2ZNZjlQSFlwOWVheFgxOG1ZZHEwUUU4MEFRLUd2aVBsMFZ0akVmUlFMQ1ZjZE52aFFtYw?oc=5", "source_name": "Reuters", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): focus on Afrezza growth and partnership pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSXpJUEowR2x0QXVzSWhNZl9QNmhaREo2TXFHWU53Z0tzdWNRbnVsY0U4U0NEWklEQndJS2xlOU9uV0FRcjZTdVhycDhIUTBGVlkxQVNpeFJFN0NUMVg3NUl2d29uSjc5dmEwZFB4ZUhoYkNtaEdjdXNMdXhLRWNwb2FqWXp4Vk5VTTJtYnY2N2FTX3FwakZfVmZzRkxZT3RHcWl6TjVpd1l2OHdOeExGSHZVajJSNWlBWHBV?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPU2ZrVGpidnZ2Y1U4LTU4NFptSzItaDZ1YjFSaU0wSlB3cURNS2ZIMHBRYkFPQ3pBSlozdmxjbGFMMG1JZEliQUs1NzJUbkh6aTFNOW1hcURZVnM3MGh4MHZGZ0JudGQzdzZpRUlJUkFlZFhaOWdRNWwtSFROdEZ6a29ORFJXWW1COXlhTWpmU3NrMnFpLUlMdnRB?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "State Street (NASDAQ: MNKD) holds 18.68M shares, 6.1% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNM1IyY3dOcDBXSjdqT1VxUlJwYjdEblZic05XQkkzbjFoOGFKV1J3NHQtbGc4RHNxX05KSWp3Y1pJRm1WYXYwSmRrUklpQ29Janl0dVQzMmVzal9paWNJN3RoNDhtUnk1QmhCVlN1OVFxdUtyTFB1dWlZSTB2dG1fMmtJZXgzZk5PU01FWlJSTEtOVjI0dGM2UDhKemhwVjYwVzJuRHZWeFdfU3AzUGFuYTg4dHNfSFpfbU02Xw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind Corp stock (US5638651064): Q1 2026 earnings miss on EPS, revenue up 15%", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQblZKYk9UdGZvR2FsZ2V6akhIZ0N6Skx4MUdIV3FXaFNKRDE1c0RMQ0NmWHBSbzlIbDRELTRpUDYzXzd3a3J0eWIybWJIWE16OW9WV3I4MGxjT2l5YWlMVS0zeWxIMlRIQ29oNUlmSkp3UFBobVNGSnZCS2lFU0ZUNFRVMmZuUGpjRU96aVlPUWJEOHR3N0JuMXVuVU9aWU8tcXlQaUkwLVZJOF92S0hNX2tXd0ozR18wNnRCU1gyYzcxM1RTQkln?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQMWtSVS1WaXZBcWJUX0ZuN1Q4XzdIQWM4RWdUeTdtc3hWY3NnUnF6ajV2TGlBNWNFeUJVT2pHNC0wSmt1aWdOdlRtaDJtUHdJNkpxUUtxd1owQ0tlMDg3cThGQlA5WW56bVlhbms2LURqZ1hya2VwNGF6T1NackEtbmsyU2Q1SEdCUzVqcnVZY1c0Z0JnbkE?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind stock drops after Q1 2026 miss (MNKD:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOX1dLUHc5bk5wZzJjVHJkQ3RHV2dBMDlGMlRtelhmQVN3OExTeWZ3LUg0a0s2MnZneEcwQl9LQ3lsS05uZjdyQ185aW5yaC04WkNnelBub01QTEw5NkE5S1AzSU81Ukdoc0ZhTExBMkRmMkhCWDBPcnprajhjYU1YV1NEUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind stock surges on United Therapeutics partnership deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWEdUSkFDa3RRbWZYc3ZTelJ5dk8yYVhkM0ZSV0VQNnhheWsyVEl5eS1SUDhzMXg5dlAxZVJPLUk4Z0c2WDlRdnFON2hkM19rSTl3OTJKczFhb2Q1WVpIS21Pb0gxVk1PVUZaZXNSODkxT2cxeDEzTGZxN09YcXhXWE13VGtWdFppbk5UcjNCUlZxYktFUThCV3lVNlliN1M0X3hOX3NFbjNVVW1rZVZXbmFSWW9ETVJ4c3hRNk5sVDI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPdE9LWFRBRV83YTd3X2g5OEhWRFNvT0NsLWNPY1o2VE9fS0xiNHdlbnEzdjZvbjF3d1d6WFZGUXM1MHFmVk5vWnY5QlRMbTcxNnRObjAxdG9VS1RUcTlCQmtoWktCV0NocG1yX3lPT1pxcm02bEpkRXRSUVdGVnhPU213cXVQMXNEVmNJanBpUWN2T1RtcHc4aXpB?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks Facing FDA Decision In May\u2014MannKind (MNKD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPblNOZlA2T2pvZUlrV3J2WlAxYTFrcWpEUkFQbTVXWGhRWjlZQldCdzVJakR2ZzFodF9pMTFTaUt6YmtUMVY4UnJOOFp0bm1OSm9WWHl6R19IekswRkNSd2tib2xCNHJCQkJiYlhfSVNQSlFodHQtLTBCR0V6ZXB0MUk0Q3FhSkF6OUJ0WjJveFlCOVNGekhHTkxPYy1mS3RTTmw0YWwxNEJBbUs4MWhTd0hOaEpHaVVLMk1IRA?oc=5", "source_name": "Forbes", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPOGhUd3pXZERualk4N0pCQXpIZVBTR3NINTFQNGZYN0I2ZWFXS1pVUjJhclZHQmpIRThELUJlc1JzQ0ozZGRHYjQ2U3JEaEowUmJ4RlZVd2N3UG5zT1JSbEltLXNhQlRkblF2RjNDaGw2RThZUnE0UDhwOEEzV01jTkJVajNoZ0p3ZVVkLWEzNDNLUXJwZGlfYVFvRkN5aEFxaE9LSnE5aHQ1Y0MwT0E?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOYXRhNDExdGRiQlZDTndJa3ZVeDNrSEtzbjdCeXpUS2FoR215eEtJb0xCY0dERVlzdndfdC0xNTRTcE5RY2lZeFNDcndVNWtXNzd2UU16NDEtRlo0anF6Nzl1VGpweXBOeU8yZ2FzenpQcUZBX2FSNl9ZR1BuTEhwZmNkcmw2cnlSV2lPU2g2SHFESi1tNnFPVEVPZ3lYOURaZlE?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNbFV0VTBKRllmY3RSZEJJVmZOdWYtMXpUOUVRLUEwejJJRjNtdmFVX3VfRzNVOGZTOU1QTUdLNHRjYzBFS2FVNF90eHpUQklJdXRHNlZaeW1OY19zdlc3NlBjXzlNbVBoME9YanRfN0JoN3czTnFoY254ZUV2bUpZNHZYN09SNllyZDcxU05YdExyYlQ0NWk3bWpnYnJhdFU?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 106, "total_relevant": 71, "sentiment_summary": {"positive": 26, "negative": 9, "neutral": 36, "score": 57, "total": 71, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 21.05, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 5.5, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 26, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 4.09, "latest_week": "2026-07-10", "one_week_move": -9.5, "four_week_move": 11.7, "twelve_week_move": 44.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.805955, "market_dynamics_buy_signal": false, "relative_strength": -21.235827, "fair_value_gap": -13.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 58.3761, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.5% over one week, +11.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "Insider Monkey", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "Ad Hoc News", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 63}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 10}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "63", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.5% over one week, +11.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval"}], "updated_at": "2026-07-16T11:51:04.535822+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}